Immucell (ICCC) Price & Analysis

Immucell Corp. released its earnings results on Nov 13, 2025. The company reported -$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.015.

Is Immucell Corp. overvalued?

According to Wall Street analysts Immucell Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immucell Corp. pay dividends?

Immucell Corp. does not currently pay dividends.

What is Immucell Corp.’s EPS estimate?

Immucell Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immucell Corp. have?

Immucell Corp. has 9,045,851 shares outstanding.

What happened to Immucell Corp.’s price movement after its last earnings report?

Immucell Corp. reported an EPS of -$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.744%.

Which hedge fund is a major shareholder of Immucell Corp.?

Currently, no hedge funds are holding shares in ICCC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Immucell Stock Smart Score

Neutral

Insider Transactions

Bought Shares

Worth $64.1K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

8.27%

Trailing 12-Months

Asset Growth

2.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immucell Corp.

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Immucell (ICCC) Earnings & Revenues

Historic Earnings Reports

ICCC Company Deck

ICCC Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a positive turnaround in financial performance with improved net income, gross margins, and operational efficiency. Domestic sales show positive momentum, and there is optimism surrounding the new leadership. However, challenges remain with declining total product sales and international sales, as well as inventory management concerns.View all ICCC earnings summaries